Business, Drugs and Pharmaceuticals, Free News Articles

NED Biosystems Announces Leading Infectious Disease Research Scientist Michael Mansour, MD, PhD To Serve as Medical Advisor

CAMBRIDGE, Mass. -- NED Biosystems, an innovative clinical-stage biotech company developing therapies for cancer and the novel coronavirus, is pleased to announce that Michael Mansour, MD, PhD, will serve as the Company's Medical Advisor of Infectious Disease. Dr. Mansour brings a wealth of expertise in infectious disease research where he leads an independent laboratory at the Massachusetts General Hospital (MGH). He is a leading authority guiding investigative studies on COVID-19 treatments and biomarkers which includes serving as Principal Investigator for Phase 3 COVID-19 studies.

As Medical Advisor, Dr. Mansour will direct NED's clinical trial initiative for NED-260 to establish the treatment's safety and efficacy for COVID-19 patients. NED-260 is a rationally designed, combination treatment that has the potential to address COVID-19 viral replication and entry based on its multiple mechanisms of action. Through its multifaceted approach to address major processes integral to COVID-19's progression and how it infects the cell, NED-260 may fulfill a critically important niche in the treatment and prevention of mild-to-moderate illness in the majority of people who are at risk for COVID-19 infection. NED is planning to conduct a Phase 2, randomized, placebo-controlled study of NED-260 in mild-to-moderate COVID-19 patients.*

"This study offers a chance to look at an oral treatment for COVID-19," said Dr. Mansour. "Taken directly after diagnosis, the combination is aimed at interrupting disease progression - and potentially speeding up a patient's recovery time. The trial will also explore the use of NED-260 as a potential prophylaxis, to prevent infection."

"The contribution of Dr. Mansour's expertise and considerable insight will be invaluable as we establish the safety and efficacy of NED-260 as a COVID-19 treatment," stated Rebecca Lambert, Founder and Executive Chair of NED Biosystems. "We are eager to commence the NED-260 clinical trials with Dr. Mansour's seasoned guidance. The time is now to develop an early treatment solution and preventative of infection."

"Dr. Mansour is an outstanding addition to our team of accomplished medical advisors at NED Biosystems," stated Dr. Geoffrey Ling, Office of the CEO, Scientific Advisory Board, Board of Directors, NED Biosystems and advisor to the U.S. Government's COVID-19 Task Force. "His prominence in the field of infectious disease research and deep expertise will help propel our efforts to bring our uniquely comprehensive treatments to the broader patient community. We are delighted to welcome him to the team."

Dr. Mansour leads a team of medical research scientists at the Mansour Laboratory that focuses on developing novel cellular diagnostics and therapies for invasive fungal infections. He is also a practicing physician specialized in infectious disease at MGH. Dr. Mansour obtained an MD and PhD from Boston University and completed his residency and served as a fellow at the MGH.

About NED Biosystems(TM)

Based in Cambridge, Massachusetts, NED Biosystems is a clinical-stage biotech company developing innovative treatments to provide multifaceted approaches to affect multiple key disease processes. Beginning with a focus on patients and their families, NED seeks to dramatically improve patient outcomes with combination treatments comprised of agents with well-established safety and tolerability profiles. NED's treatment approach is to afford patients high quality of life. Due to ease of oral dosing and cost-effectiveness of the treatments, the company aims to provide revolutionary, efficacious treatment solutions to patients not only in the U.S. and other developed nations, but also in economically challenged regions globally.

For more information, visit https://nedbiosystems.com/.

For additional information regarding this press release, please contact Creative Director, Brett Macias at bmacias@nedbiosystems.com.

*NED-260 is pending approval by the FDA post clinical trials.

PHOTO link for media: https://www.Send2Press.com/300dpi/20-1006s2p-ned-michael-mansour-300dpi.jpg

Caption: Michael Mansour, MD, PhD, NED Biosystems' New Medical Advisor of Infectious Disease.

Related link: https://nedbiosystems.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles

Leading Experts in Cancer Research Nabeel El-Bardeesy and Razelle Kurzrock Join NED Biosystems’ Scientific Advisory Board

CAMBRIDGE, Mass. -- NED Biosystems, an innovative clinical-stage biotech company developing oral therapies for cancer and novel coronavirus, is pleased to announce that Nabeel El-Bardeesy, PhD and Razelle Kurzrock, MD have joined the Company's Scientific Advisory Board. Both Dr. El-Bardeesy and Dr. Kurzrock bring a wealth of expertise as scientific and clinical leaders in cancer research and treatments.

Dr. El-Bardeesy is Associate Professor of Medicine at the Harvard Medical School and a leading authority on the causes of cancer. Dr. El-Bardeesy also serves as the Cholangiocarcinoma Foundation Scientific and Medical Advisory Board Co-Chair. Dr. El-Bardeesy additionally is Assistant Professor at Massachusetts General Hospital Cancer Center and is an instructor at the Dana-Farber Cancer Institute. Dr. El-Bardeesy is widely published on the molecular and cellular mechanisms that drive certain types of cancer.

Dr. Kurzrock is Professor of Medicine and Associate Director for Clinical Sciences at the University of San Diego Moore Cancer Center. She leads the Center's clinical trial programs and heads its recently established Center for Personalized Cancer Therapy. Dr. Kurzrock's distinguished track record includes leading one of the largest phase one clinical trial programs at the University of Texas MD Anderson Cancer Center, where she spearheaded an innovative approach that utilized advanced molecular technologies to match patients with targeted cancer treatment that optimized the possibility for response.

"The addition of Dr. El-Bardeesy and Dr. Kurzrock to the Scientific Advisory Board further strengthens the resolve of NED's mission to innovate safe, effective and transformative treatments for cancer and other life-threatening diseases such as Covid-19," stated Rebecca Lambert, Founder and Executive Chair of NED Biosystems' Board. "As we advance NED-170 clinical trials for cholangiocarcinoma, ovarian and triple negative breast cancer to establish the product's safety and efficacy, we will rely heavily on the Scientific Advisory Board's expert guidance and direction. They will also play an instrumental role in our efforts to launch clinical trials for NED-260, a potential treatment and prophylaxis for COVID-19.*"

NED-170 is a patented investigational cancer therapy that the Company believes is the first to address and affect four key processes that advance all late-stage cancers (Stages II-IV). The same four processes that drive advanced cancers are integral to the pathology of Covid-19.

"The implementation of comprehensive clinical trials is a vitally important step in determining the safety and effectiveness of the treatments for life threatening illnesses that we are innovating at NED Biosystems," stated Geoffrey Ling, COL(ret) MD, PhD, Office of the CEO, and member of the Scientific Advisory Board and Board of Directors, NED Biosystems and member of the U.S. Government's Covid-19 Task Force. "The deep expertise of our Scientific Advisory Board provides us with the confidence that we are following the proper methods and techniques to generate a valid set of trial results."

"Dr. Kurzrock and Dr. El-Bardeesy will provide invaluable guidance on the clinical design and execution for our upcoming NED-170 trials, as well as input into the analysis of the results," stated Brian Leyland-Jones, BS, MBBS, PhD, FRACP, FRACPC, NED Biosystems Chair of the Scientific Advisory Board. "We are excited to welcome them to the Scientific Advisory Board and look forward to their support of our clinical trial initiatives."

About NED Biosystems(TM)

Based in Cambridge, Massachusetts, NED Biosystems is a clinical-stage biotech company developing innovative treatments unlike most available today. Beginning with a focus on patients and their families, NED seeks to dramatically improve patients' outcomes with therapies that lack the toxicity and side effects of today's treatments, allowing patients to retain a high quality of life. Due to ease of oral dosing and cost-effectiveness of the treatments, the company aims to provide revolutionary, efficacious treatment solutions to patients not only in the U.S. and other developed nations but also in economically challenged global regions.

For more information, visit https://nedbiosystems.com/.

For additional information regarding this press release, please contact Creative Director, Brett Macias at bmacias@nedbiosystems.com.

*NED-170 and NED-260 are pending approval by the FDA post clinical trials.

*LOGO link for media: https://www.Send2Press.com/300dpi/20-0902s2p-nedbio-300dpi.jpg

Related link: https://nedbiosystems.com/

This news story was published by the Neotrope® News Network - all rights reserved.